Abstract P211 – Table 1. Statistical analysis summary of darunavir, cobicistat, emtricitabine, and TAF after oral administration of a paediatric formulation of D/C/F/TAF FDC versus coadministration of separate commercial agents.
Parameter	DRV + COBI + FTC/TAF (reference) N	D/C/F/TAF (test) N	GMR	90% CI	Intra‐individual CV (%) of reference	Intra‐individual CV (%) of test
Darunavir
Cmax (ng/mL)	32	32	0.98	0.94 to 1.02	10.3	13.2
AUClast (ng.h/mL)	32	32	1.03	0.98 to 1.08	9.6	9.5
Cobicistat
Cmax (ng/mL)	32	32	0.94	0.90 to 0.98	14.2	14.5
AUClast (ng.h/mL)	32	32	0.97	0.93 to 1.02	11.0	10.7
Emtricitabine
Cmax (ng/mL)	32	32	0.99	0.94 to 1.04	17.6	17.6
AUClast (ng.h/mL)	32	32	1.01	0.99 to 1.02	6.3	5.8
TAF
Cmax (ng/mL)	32	32	1.05	0.91 to 1.22	56.9	49.3
AUClast (ng.h/mL)	32	32	1.13	1.07 to 1.20	23.1	14.8

COBI, cobicistat; CV, coefficients of variation; DRV, darunavir; FTC, emtricitabine.